229 results on '"Biesma B"'
Search Results
2. 1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)
3. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19)
4. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin–gemcitabine or carboplatin–paclitaxel: NVALT-3 a phase III study
5. Brain metastases (BM) development after chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC): Does the type of chemotherapy matter?: 115PD
6. LBA50 A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22
7. A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naive patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22
8. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975
9. A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation
10. Cumulative pemetrexed dose increases the risk of nephrotoxicity
11. Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)
12. Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923)
13. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study
14. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
15. Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: an EORTC phase II study (EORTC 08958)
16. The value of [ 18F]fluoro-2-deoxy- d-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment
17. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
18. LBA92 - Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)
19. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy
20. Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923
21. 115PD: Brain metastases (BM) development after chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC): Does the type of chemotherapy matter?
22. PROCLAIM : résultats finaux de survie globale de l’essai de phase III : pemetrexed cisplatine ou étoposide cisplatine, plus radiothérapie thoracique suivie d’une chimiothérapie de consolidation dans le CBNPC non épidermoïde localement avancé
23. Operative morbidity and mortality after lung resection for pulmonary cancer in Septuagenarians
24. A Randomized Phase Ii Study of Paclitaxel-Carboplatin-Bevacizumab (Pcb) with or Without Nitroglycerin Patches (Ntg) in Patients (Pts) with Stage Iv Non-Squamous-Non-Small Cell Lung Cancer (Ns-Nsclc)(Nvalt 12), Impact of Circulating Vascular Endothelial Growth Factor (Vegf) Levels
25. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975
26. A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study
27. Comorbidity in lung cancer patients: Trends and effect on prognosis
28. Large Age, Socioeconomic and Hospital-Dependent Variation in Administration of Chemotherapy for Stage IV NSCLC
29. Detrimental Effects of Prechemotherapy Filgrastim
30. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chomtherapy course in patients with small-cell lung carcinoma(see comments)
31. A Randomized Phase II Study Comparing Erlotinib (E) Versus e Alternating with Chemotherapy in Relapsed Non-Small Cell Lung Cancer (NSCLC) Patients. The NVALT10 Study
32. RECOMBINANT HUMAN INTERLEUKIN-3 TO DOSE-INTENSIFY CARBOPLATIN AND CYCLOPHOSPHAMIDE CHEMOTHERAPY IN EPITHELIAL OVARIAN-CANCER - A PHASE-I TRIAL
33. 3049 POSTER Epoetin Alfa and Darbepoetin Alfa in Clinical Practice in Patients With Chemotherapy Induced Anemia in the Netherlands (EVALUATE)
34. SEROTONIN, CATECHOLAMINES, HISTAMINE, AND THEIR METABOLITES IN URINE, PLATELETS, AND TUMOR-TISSUE OF PATIENTS WITH CARCINOID-TUMORS
35. PHARMACOKINETICS OF RECOMBINANT HUMAN INTERLEUKIN-3 ADMINISTERED SUBCUTANEOUSLY AND BY CONTINUOUS INTRAVENOUS-INFUSION IN PATIENTS AFTER CHEMOTHERAPY FOR OVARIAN-CANCER
36. Platinum-based combination chemotherapy in the treatment of older non-small cell lung cancer (NSCLC) patients (pts): Is there a role for Complete Geriatric Assessment (CGA)? Final results from the prospective multicenter NVALT-3 study
37. A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study
38. Pneumonectomy for bronchogenic carcinoma: analysis of factors predicting short- and long-term outcome
39. RECOMBINANT INTERFERON-ALPHA-2B IN PATIENTS WITH METASTATIC APUDOMAS - EFFECT ON TUMORS AND TUMOR-MARKERS
40. EFFECTS OF INTERLEUKIN-3 AFTER CHEMOTHERAPY FOR ADVANCED OVARIAN-CANCER
41. A randomized phase II study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second line treatment for patients (pts) with advanced non-small-cell lung cancer (NSCLC)- NVALT 7
42. EFFECTS OF RECOMBINANT HUMAN INTERLEUKIN-3 IN PATIENTS WITH RELAPSED SMALL-CELL LUNG-CANCER TREATED WITH CHEMOTHERAPY - A DOSE-FINDING STUDY
43. ACUTE-PHASE RESPONSE IN PATIENTS GIVEN RHIL-3 AFTER CHEMOTHERAPY
44. O.14 Few differences in treatment, but a worse overall survival for cancer patients with COPD
45. COPD in cancer patients: Higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient
46. 3074 POSTER Pulmonary resection for metastases from colorectal cancer
47. B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)
48. Can baseline complete geriatric assessment (CGA) predict toxicity in elderly non-small cell lung cancer (NSCLC) patients (pts) receiving combination chemotherapy? Results from the first 100 pts in the prospective multicenter NVALT-3 study
49. Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: A population-based study in the Netherlands
50. Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.